

Table 2. Cumulative incidences of acute and chronic GVHD according to GVHD prophylaxis type.

	Cumulative incidence*	Hazard Ratio	95% Confidence Interval	P
Acute grade II-IV GVHD				
PTCy-based	23.7%	1		
CNI-MTX	45.3%	2.28	1.81-2.87	<0.001
CNI-Sirolimus	37.1%	2.01	1.52-2.66	<0.001
ATG-based	30.5%	1.39	0.99-1.95	0.06
Acute grade III-IV GVHD				
PTCy-based	6.1%	1		
CNI-MTX	8.9%	1.64	1.02-2.66	0.04
CNI-Sirolimus	5.1%	1.51	0.83-2.75	0.18
ATG-based	11.9%	2.11	1.22-3.66	0.008
Chronic global GVHD				
PTCy-based	34.0%	1		
CNI-MTX	47.6%	1.54	1.22-1.94	<0.001
CNI-Sirolimus	46.6%	1.32	1.00-1.74	0.05
ATG-based	34.5%	1.07	0.73-1.55	0.74
Moderate-to-severe chronic GVHD				
PTCy-based	19.7%	1		
CNI-MTX	37.5%	2.07	1.58-2.71	<0.001
CNI-Sirolimus	27.2%	1.54	1.07-2.20	0.019
ATG-based	26.0%	1.35	0.88-2.08	0.17

*Cumulative incidence at +100 days for acute GVHD, and at 2 years for chronic GVHD.

PTCy, Post-transplant cyclophosphamide; CNI, Calcineurin inhibitors; MTX, Methotrexate; ATG, Antithymocyte globulin.